Although many kinds of therapies are applied in the clinic, drug-resistance is a major and
unavoidable problem. Another disturbing statistic is the limited number of drug targets, which …

Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from
cure in> 90% of patients with low risk disease to< 50% for those with high risk disease …

Chimeric antigen receptor‐T (CAR‐T) cell immunotherapy has shown impressive clinical
outcomes for hematologic malignancies. However, its broader applications are challenged …

We explored the utility of targeting anaplastic lymphoma kinase (ALK), a cell surface
receptor overexpressed on pediatric solid tumors, using chimeric antigen receptor (CAR) …

Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …

The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many
cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer …

Background Various human cancers have ALK gene translocations, amplifications, or
oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic …

Neuroblastoma (NB), the most common extracranial tumor of childhood, is a cancer of
primordial neural crest cells that give rise to sympathetic neural ganglia and adrenal …

Anaplastic lymphoma kinase (ALK) activation has been associated with many types of
human cancer. Significant efforts have been devoted to the development of ALK inhibitors to …

Neuroblastoma is a pediatric solid cancer of heterogeneous clinical behavior. The unique
features of this type of cancer frequently hamper the process of determining clinical …